FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Grygiel Nancy A. 2. Issuer Name and Ticker or Trading Symbol AMGEN INC [ AMGN ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
SVP & CCO
(Last)         (First)         (Middle)
ONE AMGEN CENTER DRIVE
3. Date of Earliest Transaction (MM/DD/YYYY)
7/31/2020
(Street)
THOUSAND OAKS, CA 91320
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  7/31/2020    A    8174  A $0  11316  D   
Common Stock  8/3/2020    F    290  D $244.67  11026 (1)(2) D   
Common Stock                 88.7842 (3) I  401(k) Plan 

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
(1)  These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 159 RSUs which fully vest on 5/1/2021; 302 RSUs which vest in installments of 149 on 4/27/2021 and 153 on 4/27/2022; 452 RSUs which vest in two installments of 149 on 5/3/2021 and 5/3/2022 and one installment of 154 on 5/3/2023; 423 RSUs which vest in installments of 139 on 5/5/2022, 140 on 5/5/2023 and 144 on 5/5/2024; and 8,174 RSUs which will vest in two installments of 2,697 on 7/31/2022 and 7/31/2023 and one installment of 2,780 on 7/31/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
(2)  These shares include 55 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
(3)  These are shares acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Grygiel Nancy A.
ONE AMGEN CENTER DRIVE
THOUSAND OAKS, CA 91320


SVP & CCO

Signatures
/s/ Andrea A. Robinson, Attorney-in-Fact for Ms. Grygiel 8/3/2020
**Signature of Reporting Person Date
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Sep 2020 to Oct 2020 Click Here for more Amgen Charts.
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Oct 2019 to Oct 2020 Click Here for more Amgen Charts.